A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
about
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
P2860
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase II study of bendamusti ...... ted with rituximab: BRB study.
@en
type
label
A phase II study of bendamusti ...... ted with rituximab: BRB study.
@en
prefLabel
A phase II study of bendamusti ...... ted with rituximab: BRB study.
@en
P2093
P2860
P1476
A phase II study of bendamusti ...... ted with rituximab: BRB study.
@en
P2093
Akaru Ishida
Aya Nakaya
Hideaki Nakajima
Hironori Ueno
Keio BRB Study Group
Kenji Yokoyama
Kenko Chen
Kentaro Watanabe
Kimihiro Matsumoto
Masao Hagihara
P2860
P2888
P304
P356
10.1007/S12185-015-1767-3
P577
2015-03-19T00:00:00Z